Nilotinib Significantly Alters CSF Biomarkers and Increases Endogenous Dopamine in Open-Label Phase I Clinical Trial in Parkinsons Disease with Dementia and Lewy Body Dementia (S40.006)

Conclusions: These results indicate that Nilotinib is a potential disease-modifying therapy in neurodegenerative diseases, and provide strong feasibility for multicenter, randomized, placebo-controlled, double blind trials in early dementia and Parkinsonism.Disclosure: Dr. Moussa has nothing to disclose. Dr. Hebron has nothing to disclose. Dr. Li has nothing to disclose. Dr. Xu has nothing to disclose. Dr. Valadez has nothing to disclose. Dr. Yasar has nothing to disclose. Dr. Rogers has nothing to disclose. Dr. Falconer has nothing to disclose. Dr. Mills has nothing to disclose. Dr. Pagan has nothing to disclose.

Source: Neurology - February 7, 2016 Category: Neurology Authors: Moussa, C., Hebron, M., Li, X., Xu, H., Valadez, E., Yasar, T.-Y., Rogers, S., Falconer, D., Mills, R., Pagan, F. Tags: Movement Disorders: Parkinson ' s Disease Clinical Trials and Therapeutics Source Type: research